Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat for Anemia in Myelodysplastic Syndromes (MDS)
NCT05568225Phase 2Terminated
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of etavopivat in anemia, sponsored by Forma Therapeutics, Inc. Primary endpoint: Hematologic Improvement- Erythroid Response at 24 weeks. Started Nov 2022; status: terminated.
02
Drugs
etavopivat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05568225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568225.